NBIX vs. GMED
NBIX (Neurocrine Biosciences, Inc.) and GMED (Globus Medical, Inc.) are both stocks. Both are in the Healthcare sector — NBIX in Drug Manufacturers - Specialty & Generic, GMED in Medical Devices. Over the past 10 years, NBIX returned 12.71%/yr vs 12.86%/yr for GMED. Their 0.29 correlation means their historical movements had little consistent relationship.
Performance
NBIX vs. GMED - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NBIX achieves a 17.61% return, which is significantly higher than GMED's -9.76% return. Both investments have delivered pretty close results over the past 10 years, with NBIX having a 12.71% annualized return and GMED not far ahead at 12.86%.
NBIX
- 1D
- -10.08%
- 1M
- -0.58%
- 6M
- 22.59%
- YTD
- 17.61%
- 1Y
- 30.08%
- 3Y*
- 17.27%
- 5Y*
- 12.34%
- 10Y*
- 12.71%
- ALL TIME*
- 9.11%
GMED
- 1D
- -1.83%
- 1M
- 3.73%
- 6M
- -13.11%
- YTD
- -9.76%
- 1Y
- 49.71%
- 3Y*
- 10.13%
- 5Y*
- -1.08%
- 10Y*
- 12.86%
- ALL TIME*
- 13.68%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $96.46M | $126.87M | $149.45M | |
| $278.93M | $232.17M | $211.02M |
NBIX vs. GMED - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 17.61% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -7.96% | 100.49% |
GMED Globus Medical, Inc. | -9.76% | 5.56% | 55.21% | -28.25% | 2.87% | 10.70% | 10.77% | 36.04% | 5.30% | 65.66% |
Correlation
The correlation between NBIX and GMED is 0.16, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.16 |
Correlation (3Y) Balances recent behavior with more history. | 0.23 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.28 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.29 |
Correlation (All Time) Calculated using the full available price history since Aug 3, 2012 | 0.29 |
The correlation between NBIX and GMED shifts across timeframes, from 0.16 (1 year) to 0.29 (10 years), reflecting how their relationship changes across market environments.
Fundamentals
NBIX:
$16.77B
GMED:
$10.63B
NBIX:
$6.84
GMED:
$4.28
NBIX:
24.39
GMED:
18.39
NBIX:
0.48
GMED:
0.19
NBIX:
5.10
GMED:
3.48
NBIX:
4.35
GMED:
2.30
NBIX:
$3.37B
GMED:
$3.10B
NBIX:
$3.31B
GMED:
$1.58B
NBIX:
$940.50M
GMED:
$803.34M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NBIX vs. GMED — Risk / Return Rank
NBIX
GMED
NBIX vs. GMED - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Globus Medical, Inc. (GMED). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NBIX | GMED | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.10 | ||
| Sortino ratioReturn per unit of downside risk | -0.86 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.26 | -0.07 |
| Calmar ratioReturn relative to maximum drawdown | 1.45 | 2.26 | -0.81 |
| Martin ratioReturn relative to average drawdown | 3.18 | 4.92 | -1.74 |
Loading charts...
Drawdowns
NBIX vs. GMED - Drawdown Comparison
The maximum NBIX drawdown since its inception was -97.21%, which is greater than GMED's maximum drawdown of -47.91%. Use the drawdown chart below to compare losses from any high point for NBIX and GMED.
Loading charts...
Drawdown Indicators
| NBIX | GMED | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.21% | -47.91% | -49.30% |
Max Drawdown (1Y)Largest decline over 1 year | -20.90% | -22.10% | +1.20% |
Max Drawdown (3Y)Largest decline over 3 years | -42.89% | -44.40% | +1.51% |
Max Drawdown (5Y)Largest decline over 5 years | -42.89% | -47.91% | +5.02% |
Max Drawdown (10Y)Largest decline over 10 years | -46.39% | -47.91% | +1.52% |
Current DrawdownCurrent decline from peak | -10.08% | -18.62% | +8.54% |
Average DrawdownAverage peak-to-trough decline | -43.66% | -15.35% | -28.31% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.47% | 10.13% | -0.66% |
Volatility
NBIX vs. GMED - Volatility Comparison
Neurocrine Biosciences, Inc. (NBIX) has a higher volatility of 14.12% compared to Globus Medical, Inc. (GMED) at 12.47%. This indicates that NBIX's price experiences larger fluctuations and is considered to be riskier than GMED based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NBIX | GMED | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.12% | 12.47% | +1.65% |
Volatility (6M)Calculated over the trailing 6-month period | 26.01% | 26.28% | -0.27% |
Volatility (1Y)Calculated over the trailing 1-year period | 33.74% | 49.44% | -15.70% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.17% | 38.45% | -5.28% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 39.18% | 35.41% | +3.77% |
Dividends
NBIX vs. GMED - Dividend Comparison
Neither NBIX nor GMED has paid dividends to shareholders.
Financials
NBIX vs. GMED - Financials Comparison
This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Globus Medical, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NBIX vs. GMED - Profitability Comparison
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported a gross profit of 935.80M and revenue of 959.00M. Therefore, the gross margin over that period was 97.6%.
GMED - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Globus Medical, Inc. reported a gross profit of 0.00 and revenue of 759.85M. Therefore, the gross margin over that period was 0.0%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported an operating income of 151.50M and revenue of 959.00M, resulting in an operating margin of 15.8%.
GMED - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Globus Medical, Inc. reported an operating income of 150.39M and revenue of 759.85M, resulting in an operating margin of 19.8%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported a net income of 144.40M and revenue of 959.00M, resulting in a net margin of 15.1%.
GMED - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Globus Medical, Inc. reported a net income of 124.30M and revenue of 759.85M, resulting in a net margin of 16.4%.
Frequently Asked Questions
NBIX and GMED have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NBIX has higher volatility (14.12%) compared to GMED (12.47%). In terms of maximum drawdown, NBIX dropped -97.21% vs GMED's -47.91%.
GMED currently has the higher Sharpe Ratio (1.01 vs 0.91), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NBIX and GMED
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer